Celltrion
Clinical trials sponsored by Celltrion, explained in plain language.
-
New study checks safety of injectable remsima for arthritis and psoriasis
Disease control OngoingThis study is observing about 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who are taking Remsima (a biologic drug) either as a shot under the skin or through an IV. The goal is to track any serious side effects over time. Resear…
Sponsor: Celltrion • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New biosimilar aims to rival cosentyx for psoriasis
Disease control OngoingThis phase 3 trial tests whether CT-P55, a biosimilar of secukinumab, works as well as the approved drug Cosentyx for moderate to severe plaque psoriasis. 153 adults with chronic psoriasis for at least 6 months are receiving either CT-P55 or Cosentyx injections. The main goal is …
Phase: PHASE3 • Sponsor: Celltrion • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New diabetes drug combo tested in humans for first time
Knowledge-focused OngoingThis Phase 1 trial tests two experimental drugs (L03RD1 and L03RD2) in 48 healthy adults to see how safe they are and how the body processes them. Participants take the drugs alone or together in a single dose. The study does not aim to treat diabetes, but to gather information f…
Phase: PHASE1 • Sponsor: Celltrion • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Healthy men test two injection methods for new drug
Knowledge-focused OngoingThis study tests if giving the drug CT-P52 with an auto-injector works as well as using a pre-filled syringe. It involves 218 healthy men aged 19 to 55. The goal is to see how the drug moves through the body and if it is safe with both methods.
Phase: PHASE1 • Sponsor: Celltrion • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Healthy volunteers help compare new biosimilar to taltz
Knowledge-focused OngoingThis study tests whether a new biosimilar medicine (CT-P52) works similarly to the approved drug Taltz in the body. It involves 218 healthy adults aged 19 to 55 who receive a single dose of either the biosimilar or Taltz. The main goal is to compare how the drug is absorbed and i…
Phase: PHASE1 • Sponsor: Celltrion • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC